Yes. The reader is diagnostic-agnostic; switching to a new pathogen only requires loading the cartridge with alternative probes. The AviaSenS consortium explicitly describes the vision of “an agnostic platform capable of quantifying various communicable diseases … easily switched to emerging challenges.

The same hardware supports human health (primary care, neonatology), veterinary diagnostics (on-farm outbreak screening), food safety, and environmental surveillance. Projects highlight use in both resource-limited settings and high-income countries to shorten turnaround times and reduce costs.

Intermountain Healthcare is contracted with the majority of insurance plans for laboratory testing. These insurance plans cover the most commonly ordered lab tests. If you have a question about specific tests your physician has ordered, please contact your insurance carrier. Your physician’s billing office may also be able to tell you what out-of-pocket expenses there may be, if any.

BioEclosion holds a multi-jurisdiction patent family, e.g., “Peptide, magnetic peptide and method for detecting celiac disease” filed in Europe, the USA, Canada, and via PCT. Devices are being developed under ISO 13485 and IVDR guidance to streamline future CE-marking.